DK1015026T3 - IL-12 som en adjuvans til Bordetella pertussis-vacciner - Google Patents

IL-12 som en adjuvans til Bordetella pertussis-vacciner

Info

Publication number
DK1015026T3
DK1015026T3 DK97932137T DK97932137T DK1015026T3 DK 1015026 T3 DK1015026 T3 DK 1015026T3 DK 97932137 T DK97932137 T DK 97932137T DK 97932137 T DK97932137 T DK 97932137T DK 1015026 T3 DK1015026 T3 DK 1015026T3
Authority
DK
Denmark
Prior art keywords
adjuvant
bordetella pertussis
pertussis vaccines
vaccines
bordetella
Prior art date
Application number
DK97932137T
Other languages
Danish (da)
English (en)
Inventor
Kingston H G Mills
Bernard P Mahon
Mark S Ryan
Fiona Griffin
Original Assignee
Nat Univ Ireland Maynooth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Ireland Maynooth filed Critical Nat Univ Ireland Maynooth
Application granted granted Critical
Publication of DK1015026T3 publication Critical patent/DK1015026T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK97932137T 1996-05-31 1997-05-30 IL-12 som en adjuvans til Bordetella pertussis-vacciner DK1015026T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1587196P 1996-05-31 1996-05-31
US82986597A 1997-03-31 1997-03-31

Publications (1)

Publication Number Publication Date
DK1015026T3 true DK1015026T3 (da) 2006-09-11

Family

ID=26687907

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97932137T DK1015026T3 (da) 1996-05-31 1997-05-30 IL-12 som en adjuvans til Bordetella pertussis-vacciner

Country Status (10)

Country Link
US (5) US6929794B1 (pt)
EP (2) EP1649868A1 (pt)
JP (2) JP3737519B2 (pt)
AT (1) ATE325621T1 (pt)
AU (1) AU724743B2 (pt)
DE (1) DE69735856T2 (pt)
DK (1) DK1015026T3 (pt)
ES (1) ES2262181T3 (pt)
PT (1) PT1015026E (pt)
WO (1) WO1997045139A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3737519B2 (ja) * 1996-05-31 2006-01-18 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー 百日咳菌ワクチン用アジュバントとしてのｉｌ―１２
AU759391B2 (en) * 1998-02-12 2003-04-10 Wyeth Holdings Corporation Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
JP2002505302A (ja) * 1998-03-05 2002-02-19 ザ メディカル カレッジ オブ オハイオ Ｉｌ−１２の鼻腔内イノキュレーションによる免疫の増強
US5985264A (en) * 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
WO2000069456A2 (en) * 1999-05-13 2000-11-23 American Cyanamid Company Adjuvant combination formulations
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
US7374751B1 (en) * 2000-06-22 2008-05-20 Wyeth Holdings Corporation QS-21 and IL-12 as an adjuvant combination
HUP0600589A2 (en) * 2000-11-10 2006-11-28 Wyeth Corp Adjuvant combination formulations
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
US20080138833A1 (en) * 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
ES2331271B1 (es) * 2007-06-29 2010-10-14 Universidad Del Pais Vasco Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas.
DK2670432T3 (da) * 2011-02-04 2021-04-19 Zoetis Services Llc Immunogene Bordetella bronchiseptica-sammensætninger

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
CA1340373C (en) * 1986-01-28 1999-02-02 Rino Rappuoli Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin
US4705686A (en) * 1986-05-09 1987-11-10 American Cyanamid Process for the preparation of acellular Bordetalla pertussis vaccine
JPH01193231A (ja) * 1988-01-27 1989-08-03 Takeda Chem Ind Ltd 抗腫瘍剤
DE68926859T2 (de) 1988-11-10 1997-02-13 Genetics Inst Natürlicher killerzellen-stimulationsfaktor
US5162223A (en) * 1989-02-17 1992-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Resources Hybridomas and resulting monoclonal antibodies directed against antigens of Bordetella pertussis
KR0177179B1 (ko) * 1989-07-14 1999-03-20 알퐁스 아아르 노에 인터루킨을 함유하는 안정한 백신 조성물
GB9007657D0 (en) * 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
WO1994001139A1 (en) 1992-07-13 1994-01-20 Baylor College Of Medicine Targeting somatic gene therapy to joints
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
ATE229978T1 (de) 1994-07-01 2003-01-15 Chiron Corp Helicobacter proteine und impstoffe
WO1996010423A1 (en) 1994-09-30 1996-04-11 Ludwig Institute For Cancer Research COMPOSITIONS CONTAINING A p53 DERIVED PROTEIN OR PEPTIDE, AN ADJUVANT, AND INTERLEUKIN-12 AND USES THEREOF
DE69534922T2 (de) * 1994-10-05 2006-11-23 Vanderbilt University, Nashville Interleukin-12 als adjuvans für paramyoxviridae impfstoffe
WO1997000321A1 (en) 1995-06-14 1997-01-03 Commonwealth Scientific And Industrial Research Organisation Immune response modulators and uses therefor
JP3737519B2 (ja) * 1996-05-31 2006-01-18 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー 百日咳菌ワクチン用アジュバントとしてのｉｌ―１２

Also Published As

Publication number Publication date
PT1015026E (pt) 2006-08-31
JP2005112865A (ja) 2005-04-28
DE69735856T2 (de) 2006-11-16
WO1997045139A2 (en) 1997-12-04
WO1997045139A3 (en) 1998-02-12
EP1649868A1 (en) 2006-04-26
EP1015026B1 (en) 2006-05-10
EP1015026A2 (en) 2000-07-05
ES2262181T3 (es) 2006-11-16
JP2001527516A (ja) 2001-12-25
AU724743B2 (en) 2000-09-28
US6929794B1 (en) 2005-08-16
US20060257419A1 (en) 2006-11-16
JP3737519B2 (ja) 2006-01-18
US20060263379A1 (en) 2006-11-23
US20060263380A1 (en) 2006-11-23
ATE325621T1 (de) 2006-06-15
AU3567097A (en) 1998-01-05
US20050158276A1 (en) 2005-07-21
DE69735856D1 (de) 2006-06-14

Similar Documents

Publication Publication Date Title
DK1015026T3 (da) IL-12 som en adjuvans til Bordetella pertussis-vacciner
ITRM930316A0 (it) Dina radiografico-chirurgica orientabile per ipianti nelle ossa mascellari.
NL300186I1 (nl) Acellulair vaccin.
FI954514A (fi) 3-O-deasyloitua monofosforyylilipidiä A sisältävä rokotekoostumus
DE69634024D1 (de) Adjuvans für vitale Impfstoffe
NO912713D0 (no) Effektive vaksiner mot bordetella pertussis omfattende enkombinasjon av individuelt rensete pertussis-antigener.
MX9204078A (es) Metodo y composicion para la prevencion de la enfermedad de lyme.
DK0745388T4 (da) Mammalt vaccinepræparat omfattende squalen eller squalan, phospholipid og et overfladeaktivt stof som adjuvans
DK0939648T3 (da) Rotavirusvaccineformuleringer
NO892997D0 (no) Bordetella pertussis vaksine.
PT757556E (pt) Bacterina borrelia burgdorferi
NO910357D0 (no) Innretning til feilmoensterregenerering ved "soft"-desisjonsdekoding av blokkoder.
FR2719998B1 (fr) Composition immunisante anti-hélicobacter pylori à base de catalase.
ES2136443T3 (es) Limpieza in situ.
EP0563288A4 (en) Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines
FI914433A0 (fi) Gen som kodar ett 30 kilodaltons yttermembranprotein fraon bordetella pertussis.
IT220039Z2 (it) Dispositivo di supporto ammortizato, per avvitatori e simili
HUP9902885A1 (hu) Maláriaellenes vakcinakészítmények